Secondary Data. In its evaluation activities, CMS may use data or information submitted by the ACO as well as claims submitted to CMS for items and services furnished to Next Generation Beneficiaries. This data may include, but is not limited to:
(a) Survey data from CAHPS surveys;
(b) Clinical data such as lab values;
(c) Medical records; and
Secondary Data a) Secondary data that directly affect the potential distribution of a pest or disease can be used to determine the potential area of infestation. Secondary data will only be used if all parties on the NBMCC agree and only if it is available, highly relevant and incontrovertible.
b) Secondary data includes: i) insolation ii) humidity iii) land use
Secondary Data. In its evaluation activities, CMS or its designee(s) may use data or information submitted by the Hospital for quality and monitoring purposes as well as claims submitted by practitioners, providers and suppliers to CMS for items and services furnished to Maryland Medicare Beneficiaries. These data may include, but are not limited to:
(i) Claims data;
(ii) Survey data;
(iii) Medical records including clinical data such as lab values; and
(iv) Quality and clinical data submitted via the Hospital’s CRP Report.
Secondary Data. The Parkview Health CHNA Dashboard1, developed by Healthy Communities Institute, was used to access secondary data. Additional state and national secondary data sources were accessed for more recent and geographically-specific information, including the following: • Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (CDC-NCHHSTP) Atlas: A federal source of data regarding sexually transmitted infections and diseases.
Secondary Data. We reduced the initial eight documents to six documents, because a short initial review of the documents showed that the DESCA-A (B) and the DESCA-B (C) CAM are largely redundant. Hence, we decided not to include the uncommented version DESCA-B in our analysis in order to avoid negative redundancy. For the same reasons, we decided not to analyse the (D’) EUCAR-B CAM. Hence, we analysed the following six CAM’s (in alphabetical ordering):
1. A: Clean Sky 2 2. B: DESCA-2020 with Commentary 3. D: EUCAR in Horizon 2020 4. E: IMG4-2020 5. F: MCARD-2020
Secondary Data. In its evaluation activities, CMS or its designee(s) may use data or information submitted by or made available by the Participant as well as claims submitted to CMS for items and services furnished to beneficiaries. These data may include, but are not limited to:
(i) claims data,
(ii) survey data,
(iii) clinical data such as lab values,
(iv) medical records, and
(v) Clinical Protocols, Implementation Plan, or other Model implementation documents. Shared Learning Activities
(a) The Participant shall actively participate in the Learning System designed by CMS to strengthen results and share learning that emerges from participation in the Model. Specifically, the Participant shall:
(i) Participate in Learning System activities throughout the term of this Agreement, including during the period after the Effective Date but prior to the Start Date. By the end of the second quarter following the Start Date, the Participant shall develop and submit to CMS, in a form and manner specified by CMS, a visual display of what drives achievement of Participant’s implementation aim (“Driver Diagram”) designed to drive toward the achievement of project aim as well as the inclusion of objectives and key results (“OKRs”). CMS will work with the Participant to provide sufficient instruction on Driver Diagram and OKR development. The Participant shall annually update the Driver Diagram and OKRs and submit to CMS;
(ii) Respond to surveys, interviews, or other assessment mechanisms from CMS or its designees in order to assist CMS in identifying Participant learning needs;
(iii) Participate in the identification and dissemination of promising practices, challenges, and other opportunities useful for learning, peer-to-peer sharing, and overall improvement across Model Participants (e.g., presenting on webinars, spotlights, etc.);
(iv) Participate in required ET3 Model Learning System activities during the Model Performance Period, including up to one virtual Learning System activity every quarter. Repeated failure to actively participate in required Learning System activities and related events could result in remedial action and/or termination of this Agreement pursuant to Article 19;
(v) Develop, track, and report to CMS on quality improvement efforts, activities, and program measures, at regular intervals; and
(vi) Participate in at least one in-person Learning System event during the Model Performance Period. The location of each in-person event will be made at CMS’s sole dis...
Secondary Data. In its evaluation activities, CMS may use data or information submitted by the DCE as well as claims submitted to CMS for items and services furnished to Beneficiaries. This data may include, but is not limited to:
Secondary Data. Secondary data that directly affect the potential distribution of a disease can be used to determine the potential area of infection. Secondary data will only be used if all parties on the NBMCC agree and only if it is available, highly relevant and incontrovertible.
Secondary Data. (a) Secondary data that directly affect the potential distribution of a disease can be used to determine the potential area of infection. Secondary data will only be used if all parties on the NBMCC agree and only if it is available, highly relevant and incontrovertible.
(b) Secondary data includes:
(i) Knowledge of overseas hosts and geographical ranges—this can be used to infer temperature and other environmental tolerances if reliable data is not available relating to both the disease agent and potential host species.
(ii) Evidence for the tolerance of a disease agent to other limiting factors, such as temperature and salinity.
(c) If secondary data are known to limit the extent of potential distribution they should be combined with the modelling output to increase the robustness of the conclusions on potential distribution.
(d) It may also be useful to analyse a number of factors to establish the timing of management actions and response arrangements. Such factors may include:
(i) mechanisms of pathogen transmission (ii) knowledge of potential vectors (iii) natural barriers.
Secondary Data. (a) Secondary data that directly affect the potential distribution of a disease can be used to determine the potential area of infection. Secondary data will only be used if all parties on the NBMCC agree and only if it is available, highly relevant and incontrovertible.
(b) Secondary data includes:
(i) spatial information on dams
(ii) the hydrologic regime (water levels, flow, turbidity etc)
(iii) water chemistry (oxygen levels, salinity, hardness, acidity, pollution etc).
(c) If the secondary data are known to limit the extent of potential distribution they should be combined with the modelling output to increase the robustness of the conclusions on potential distribution.
(d) It may also be useful to analyse a number of factors to establish the timing of management actions and response arrangements. Such factors may include:
(i) mechanisms of pathogen transmission (ii) knowledge of potential vectors (iii) natural barriers.
